CR08010-2026

SECURITIES AND EXCHANGE COMMISSIONSEC FORM 17-Q

QUARTERLY REPORT PURSUANT TO SECTION 17 OF THE SECURITIES
REGULATION CODE AND SRC RULE 17(2)(b) THEREUNDER

1. For the quarterly period ended
Sep 30, 2026
2. SEC Identification Number
148022
3. BIR Tax Identification No.
000-288-655-000
4. Exact name of issuer as specified in its charter
Euro-Med Laboratories Phil., Inc.
5. Province, country or other jurisdiction of incorporation or organization
Metro Manila
6. Industry Classification Code(SEC Use Only)
7. Address of principal office
PPL Building, United Nations Avenue corner San Marcelino St., Manila Postal Code 1007
8. Issuer's telephone number, including area code
00-63-2-85240091 to 98
9. Former name or former address, and former fiscal year, if changed since last report
N/A
10. Securities registered pursuant to Sections 8 and 12 of the SRC or Sections 4 and 8 of the RSA
Title of Each Class Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding
common shares 4,112,140,540
11. Are any or all of registrant's securities listed on a Stock Exchange?
Yes
No
If yes, state the name of such stock exchange and the classes of securities listed therein:
The Philippine Stock Exchange, Inc.
12. Indicate by check mark whether the registrant:

(a) has filed all reports required to be filed by Section 17 of the SRC and SRC Rule 17 thereunder or Sections 11 of the RSA and RSA Rule 11(a)-1 thereunder, and Sections 26 and 141 of the Corporation Code of the Philippines, during the preceding twelve (12) months (or for such shorter period that the registrant was required to file such reports)

Yes
No
(b) has been subject to such filing requirements for the past ninety (90) days
Yes
No

The Exchange does not warrant and holds no responsibility for the veracity of the facts and representations contained in all corporate disclosures, including financial reports. All data contained herein are prepared and submitted by the disclosing party to the Exchange, and are disseminated solely for purposes of information. Any questions on the data contained herein should be addressed directly to the Corporate Information Officer of the disclosing party.

Euro-Med Laboratories Phil., Inc.EURO

PSE Disclosure Form 17-2 - Quarterly Report References: SRC Rule 17 and
Sections 17.2 and 17.8 of the Revised Disclosure Rules

For the period ended Sep 30, 2026
Currency (indicate units, if applicable) Php
Balance Sheet
Period Ended
Fiscal Year Ended (Audited)
Sep 30, 2026 Dec 31, 2025
Current Assets 5,986,683,134 5,623,063,831
Total Assets 11,453,952,520 11,144,610,477
Current Liabilities 3,739,442,169 3,832,620,971
Total Liabilities 5,038,045,685 5,076,455,877
Retained
Earnings/(Deficit)
2,253,911,421 1,906,159,188
Stockholders' Equity 6,415,906,833 6,068,154,600
Stockholders' Equity - Parent 6,231,637,655 5,933,653,304
Book Value per Share 1.56 1.48
Income Statement
Current Year
(3 Months)
Previous Year
(3 Months)
Current Year-To-Date
Previous Year-To-Date
Gross Revenue 1,942,657,304 1,731,601,989 5,248,370,335 4,980,638,129
Gross Expense 1,680,229,771 1,487,987,642 4,587,289,260 4,370,235,250
Non-Operating Income 9,856,521 6,357,351 27,037,403 17,381,475
Non-Operating Expense 79,122,012 75,165,528 228,395,961 237,216,374
Income/(Loss) Before Tax 193,162,043 174,806,170 459,722,517 390,567,980
Income Tax Expense 47,804,155 44,712,398 114,450,238 100,880,405
Net Income/(Loss) After Tax 145,357,888 130,093,772 345,272,278 289,687,574
Net Income Attributable to
Parent Equity Holder
125,846,893 115,681,908 297,984,351 271,286,325
Earnings/(Loss) Per Share
(Basic)
0.03 0.03 0.08 0.07
Earnings/(Loss) Per Share
(Diluted)
0.03 0.03 0.08 0.07
Current Year (Trailing 12 months)
Previous Year (Trailing 12 months)
Earnings/(Loss) Per Share (Basic) 0.08 0.07
Earnings/(Loss) Per Share (Diluted) 0.08 0.07
Other Relevant Information

Please see Notes 24 and 26 for breakdown of Gross Expense, Non-Operating Income and Non-Operating Expense

Filed on behalf by:
Name Janice Ong
Designation Corporate Secretary